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ABSTRACT
Telomere dysfunction drives chromosome instability through endless breakage-
fusion-bridge (BFB) cycles that promote the formation of highly rearranged 
genomes. However, reactivation of telomerase or ALT-pathway is required for 
genome stabilisation and full malignant transformation. To allow the unrestricted 
proliferation of cells at risk of transformation, we have established a conditional 
system of telomere deprotection in p16INK4a-deficient MCF-10A cells with modified 
checkpoints. After sustained expression of a dominant negative form of the shelterin 
protein TRF2 (TRF2ΔBΔM), cells with telomere fusion did progress to anaphase but no 
signs of ongoing BFB cycles were observed, thus anticipating proliferation defects. 
Indeed, 96 h TRF2ΔBΔM expression resulted in noticeable growth proliferation defects 
in the absence of cell cycle disturbances. Further transient periods of 96 h telomere 
uncapping did not result in cell cycle disturbances either. And reduction of the 
telomere damage to short acute deprotection periods did not in any case engender 
cells with a reorganised karyotype. Strikingly, the growth arrest imposed in cells 
showing dysfunctional telomeres was not accompanied by an activation of the DNA 
damage response at cellular level, or by the presence of visible markers of senescence 
or apoptosis. We propose that the deprotection of many telomeres simultaneously, 
even for a short time, results in a local activation of the cellular stress response which 
consequently triggers gradual cell withdrawal from cell cycle, restraining the onset 
of genomic instability.
INTRODUCTION
Telomeres are nucleoprotein complexes that cap 
the ends of chromosomes, thus preventing illegitimate 
recombination processes. By adopting a t-loop structure, 
telomeres ensure genomic stability by providing 
chromosome end protection [1, 2, and reviewed by 3]. The 
most deleterious outcome of telomere deprotection is the 
formation of chromosome end-to-end fusions, which may 
fire breakage-fusion-bridge (BFB) cycles and rampant 
chromosome instability (CIN) [4–6, and reviewed by 7]. 
In certain types of epithelial cancers, telomere dysfunction 
is considered to be a key trigger for CIN and a promoter 
of tumourigenesis [8, 9]. Specifically in the breast, studies 
support the view that telomere dysfunction can precede 
disease progression and is not simply a biomarker of 
advanced disease [10–13]. Indeed, qFISH studies have 
indicated modest telomere shortening occurring in 
hyperplasia, a more significant reduction becoming prevalent 
as early as ductal carcinoma in situ (DCIS) [14, 15], and the 
presence of significantly short telomeres in malignant breast 
cells compared to normal surrounding breast tissue [16]. 
The impact of telomeres in breast carcinogenesis is further 
supported by the detection of telomere-to-telomere fusion, 
a hallmark of telomere dysfunction, in early stage breast 
tumours, including DCIS [17].
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Telomeres that can no longer exert end-protective 
functions because of excessive telomere attrition or 
alterations in the components of the shelterin complex 
itself, are recognised as sites of DNA damage and recruit 
the same repair factors that are associated with double 
strand breaks (DSBs) at other sites of the genome [18, 
19]. Unprotected chromosome ends impinge on signalling 
kinases ATM and ATR to activate a DNA damage response 
(DDR) that via p53-p21Waf1/Cip1 or pRb-p16INK4a axis leads 
to checkpoint-mediated cell cycle arrest and senescence 
or apoptosis [20, 21]. Among the shelterin proteins, TRF2 
(telomere repeat binding factor 2) is at the heart of the 
molecular events that maintain telomere integrity in 
mammals [22–24, and reviewed by 25]. TRF2 binding 
to DNA in vitro stimulates strand invasion, adopting 
structures that resemble t-loops [2]. Furthermore, the 
frequency of t-loops in vivo is significantly reduced in cells 
lacking TRF2, implicating this sheltering subunit in its 
formation and/or stabilisation [26]. It has been previously 
reported that expression of the truncated form of TRF2 
(TRF2ΔBΔM), which lacks the Basic and Myb domains, 
interferes with the accumulation of the endogenous TRF2 
protein at telomeres [22]. Depletion of TRF2 in normal 
cells using RNAi, dominant-negative alleles or Cre-
mediated deletion typically results in a non-reversible 
telomere dysfunction phenotype that induces strong DNA 
damage signalling and stalls cell cycle progression [19, 22, 
23, 27]. Therefore, telomere dysfunction acts as a tumour 
suppressive mechanism in cells with a functional DDR 
by limiting the expansion of unstable cell populations 
harbouring precancerous mutations. In sharp contrast, 
dysfunctional telomeres in cells with a limited DDR 
might allow the proliferation of damaged cells at risk of 
transformation if telomere length is stabilised through 
telomerase activation or ALT-pathways.
With the aim of generating heavily rearranged 
but telomerase stabilised epithelial human cells, we 
generated a versatile experimental system of telomere 
deprotection where TRF2ΔBΔM expression is controlled by 
a doxycycline inducible promoter in the non-tumorigenic 
epithelial mammary cell line MCF-10A. We reasoned 
that limiting the telomere insult to brief periods might 
allow for a bypass of the acute cellular responses to 
dysfunctional telomeres. Besides that, given that telomere 
dysfunction can either prevent or promote tumourigenesis 
depending on the intactness of the DDR system, we used 
different approaches to experimentally inhibit the p53/
pRb pathways. Our results demonstrate that, after 96 h of 
sustained TRF2ΔBΔM expression, the telomere dysfunction 
phenotype increased with checkpoint protein inactivation, 
with the greatest impact seen in SV40LT transduced 
MCF-10A cells. However, evidence of chromosome 
specific structural aberrations or extensive aneuploid 
configurations compatible with ongoing BFB cycles were 
unnoticed in cells lacking p16INK4a only or along with p53 
inactivation, thus supporting the incapacity of p16INK4a-
deficient cells to cope with acute telomere damage. 
Even periods of short acute telomere deprotection did 
not dramatically alter the cell cycle profile of p16INK4a-
deficient cells or give rise to an intensification of the 
telomere-dependent CIN over time. Collectively, this 
indicates that cells experiencing transient acute telomere 
damage cannot overcome the severe proliferation defect 
imposed by uncapped telomeres and are destined to die.
RESULTS
The MCF-10A cell line is a spontaneously 
immortalised, but non-transformed human mammary 
epithelial cell line derived from breast tissue [28]. 
This cell line maintains telomere length through 
telomerase, but its expression is low [29, 30], making it 
hard to see a clear band of hTERT by western blotting 
(Supplementary Figure 1). Furthermore, despite being 
commonly recognised as normal cells, the karyotype is 
cytogenetically abnormal (Supplementary Figure 2A) 
and harbours genetic abnormalities commonly associated 
with cultured mammary epithelial cells such as deletion of 
the locus containing p16INK4a and p14ARF, as well as MYC 
amplification [31, 32].
Establishment of conditional TRF2ΔBΔM MCF-
10A cell lines with different cell cycle settings
Different MCF-10A cell lines were generated 
to display telomere dysfunction in a regulated manner 
through doxycycline (DOX)-induced expression of 
TRF2ΔBΔM (Figure 1A). The MCF-10A T/O TRF2ΔBΔM (TO) 
cell line was generated after serially transducing MCF-
10A cells with lentiviral particles containing the inducible 
TRF2ΔBΔM cassette and the rtTA3 transactivator (Figure 
1B). Because abrogation of the p53 and pRb pathways is 
needed in human cells to bypass senescence and to initiate 
rampant telomere-dependent CIN, we established a second 
MCF-10A T/O TRF2ΔBΔM inducible cell line where p53 
expression was constitutively abolished using short-
hairpin p53 RNA lentiviral particles (SH-TO) (Figure 
1B). After antibiotic selection, diminished levels of p53 
were verified through western blotting (Figure 1C and 
Supplementary Figure 3A). Besides that, inactivation of 
the p53 pathway was confirmed by the fact that increased 
levels of p53S15 and p21Waf1/Cip1 were practically unnoticed 
after cell exposure to the DSBs inducer Bleocin™ (Figure 
1C and Supplementary Figure 3A) and by the increased 
ability of tetraploid cells to re-enter the cell cycle and 
initiate another round of DNA replication after 24 h 
colcemid exposure and release (Supplementary Figure 
4). Moreover, as an independent way of inactivating the 
pRb and p53 pathways, we generated a third TRF2ΔBΔM 
conditional MCF-10A model (SV-TO) by transducing 
TO cells with a lentivirus that constitutively expresses 
the Large T antigen gene from SV40 and mCherry 
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Figure 1: Generation of different MCF-10A cell lines with inducible TRF2ΔBΔM expression. (A) Scheme of the conditional 
TET-ON expression system for TRF2ΔBΔM. The doxycycline-inducible system consisted in the constitutive expression of the rtTA3 protein 
through the hUbC (Ubiquitin C) promoter and the TRF2ΔBΔM protein under the inducible CMV (Citomegalovirus)-Tetop promoter. In 
the absence of the tetracycline-derivative doxycycline (DOX), the rtTA3 protein is unable to bind to the TET-OP sequences located at 
the promoter; consequently, gene expression is repressed. In contrast, when DOX is added to the cell culture, it binds to rtTA3, which 
subsequently undergoes a conformational change that allows it to bind to the inducible promoter, starting TRF2ΔBΔM transcription. (B) All 
cell lines (TO; SH-TO and SV-TO) contained the doxycycline-expression system. In addition to these modifications, SH-TO cell lines were 
transduced with the short hairpin RNA of p53 under the hU6 constitutive promoter. And the SV-TO cell line expressed the SV40 Large 
T antigen and mCherry under the CAG (CMV enhancer-chicken beta actin) constitutive promoter. All constructs contained a selectable 
marker or a resistence gene for selection purposes, under the same or a different promoter. The inducible MCF-10A cell lines (TO; SH-TO; 
SV-TO) were generated through serial transduction with TRF2ΔBΔM (passage 19), rtTA3 (passage 22), shp53 (passage 21) or SVLT40-
mCherry (passage 25 and 30) lentivirus. (C) Immunoblots of untreated and DOX- or Bleocin™-treated MCF-10A and TO, SH-TO and 
SV-TO cell lines. Diminished levels of p53 were observed in the SH-TO cell line as well as reduced levels of p53S15 and p21Waf1/Cip1 after 
DSBs induction by Bleocin™, thus validating short hairpin RNA p53 inactivation. In SV-TO cells, western blots confirmed the presence 
of SV40 Large T antigen. In this cell line, higher p53 and p53S15 levels are observed due to p53 stabilisation by LT antigen. After DSBs 
induction by Bleocin™ exposure, both TO and SV-TO cells showed enhanced p53S15 and p21Waf1/Cip1 levels. The loss of the G1 growth 
suppressor function of pRb was determined by the ratio between pRbS807-811/total pRb. Cell lines containing the SV40LT antigen showed 
higher pRbS807/811 levels than uninfected cell lines, thus supporting inactivation of pRb protein. (D) SV-TO cells were selected by FACS of 
cells expressing mCherry. SV40LT-mCherry uninfected TO cells were used as control to discard cell autofluorescence. The FACS profile of 
SV-TO MCF-10A cell line shows weakly and strongly mCherry expressing populations. For the following experiments, SV-TO cells with 
strong mCherry expression were used. (E) SV40 T-antigens (st+LT) immunofluorescence in SV-TO cells 24 h and one week after FACS 
sorting. Immunofluorescent images, captured under the same exposure conditions, denote the partial loss of T-antigen expression over time. 
Scale bar corresponds to 20 μm.
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(Figure 1B). The translation product of SV40LT functions 
as a viral oncoprotein, which upon binding to p53 and 
pRb proteins inhibits their functions [33]. Selection 
of SV40LT containing cells was done by fluorescence 
activated cell sorting (FACS) of mCherry positive cells 
(Figure 1D) and afterwards SV40LT expression was 
validated by western blot, immunofluorescence and flow 
cytometry. As expected, the Large T antigen was present 
in SV-TO whole cell extracts and detected in the nucleus 
of transduced cells by immunofluorescence (Figure 1C 
and 1E). However, we found that SV40LT expressing 
cells were gradually lost from the culture (Figure 1E). 
Additional experiments with the p16INK4a-deficient MCF-
10A cells demonstrated again the loss of SV40LT positive 
cells with time (Supplementary Figure 5A and 5B). This 
leaking effect was previously reported to occur in p16INK4a-
deficient human mammary epithelial cells (vHMECs) 
transduced with SV40 early region (st and LT antigens) 
[34, 35]. To validate this, HMECs derived from cosmetic 
breast reductions were transduced with the same SV40LT 
antigen-mCherry vector. In this case, HMECs-hTERT 
were infected at an early population doubling (PD 6.92) 
before p16INK4a inactivation takes place and we did not 
pick clones or select for mCherry cells by FACS. In those 
HMECs-hTERT-SV40LT, the leaking effect was not 
observed. But most importantly, the analysis of SV40LT 
antigen levels by western blotting and flow cytometry 
at PD>92.31, demonstrated that cells were still positive 
for the Large T antigen (Supplementary Figure 5B and 
5C). As a whole, and confirming previous studies, breast 
epithelial cells p16INK4a-deficient are refractory to SV40 
transformation. The reason why this occurs is unknown 
and further experiments would be needed to ascertain it.
Even though the generation of a stable SV-TO cell 
line over time was unsuccessful, at the time of the analysis, 
immunoblots revealed the presence of the SV40LT antigen 
(Figure 1C). The infection of cells with Large T antigen 
presumably renders the cells oblivious to the DNA damage 
checkpoint by inactivating both pRb and p53. SV40LT 
antigen triggers p53S15 and stabilises p53 protein, but it is 
suggested that the direct interaction between SV40LT and 
p53 inhibits its function as a transcription factor [36]. In SV-
TO cells, immunoblots demonstrated stabilisation of p53 by 
a higher expression of both p53S15 and p53 in comparison 
with the other cell lines (Figure 1C and Supplementary 
Figure 3A). However, after Bleocin™ treatment the cells 
were capable of upregulating p53S15 and p21Waf1/Cip1 (Figure 
1C and Supplementary Figure 3A). Given that it was not 
clear whether upregulation was due to the improper p53 
pathway inactivation or to the presence of SV-TO cells 
lacking the SV40LT antigen, the response of SV-TO cells 
to acute colcemid treatment was also evaluated. Coincident 
with SH-TO cells, a significant polyploid population was 
observed in SV-TO cells 48 h after colcemid treatment 
(Supplementary Figure 4) thus supporting that at least the 
p53 pathway was abrogated in some cells. To determine 
the functional inactivation of the pRb pathway we tested 
the expression of the retinoblastoma pocket protein pRb 
(p105) and its phosphorylated form pRbS807/811 (Figure 
1C), as Large T antigen binds and inactivates pRb pocket 
proteins [37]. The ratio of pRbS807/811/pRb was low in those 
cells not containing the SV40LT antigen (Supplementary 
Figure 3B). In cells expressing the LT antigen, pRb was in 
a more hyper-phosphorylated state and higher pRbS807/811/
pRb ratios were detected, thus suggesting alleviation of the 
pRB-mediated repression checkpoint.
Finally, the specific genetic changes present in the 
parental MCF-10A cell line were evaluated (Supplementary 
Figure 2A). The modal karyotype at p15 was defined as 
47, XX, i(1q), del(1q), +1, der(3)t(3;9), der(8)t(8;8), 
der(9)t(9;3;5). In addition to these clonal aberrations, 
previously described in the literature [38–40], some signs 
of CIN were found. A total of 10.81% of non-modified 
MCF-10A metaphases showed non-clonal chromosome 
aberrations including chromosome fragments, chromatid 
breaks and one dicentric chromosome that showed 
telomeric FISH signals at the fusion point (Supplementary 
Table 1). Karyotyping by reverse DAPI banding was also 
performed in the uninduced TO, SH-TO and SV-TO cell 
lines to determine the cytogenetic impact of the genetic 
modifications (Supplementary Figure 2 and Supplementary 
Table 1). Collectively, these data suggested that the 
establishment of the TET-ON inducible system did not 
have a deleterious effect on the karyotype of MCF-10A 
epithelial cells. By contrast, and as previously reported 
[41], diminished levels of p53 resulted in an increase of 
cells containing chromosome aberrations with regard to the 
parental MCF-10A (Supplementary Figure 2). This adverse 
effect was markedly opposed if disruption was achieved 
through short hairpin RNA interference or SV40LT 
infection. Whereas shp53 resulted in an increase in non-
clonal unstable aberrations that included rejoined broken 
chromosomes, acentric fragments and chromosome breaks, 
SV40LT transduction resulted in clonal stable chromosome 
aberrations (Supplementary Figure 2). This divergent result 
could be explained by the time elapsed between infection 
and the cytogenetic analysis. Due to the loss of SV40LT 
expression, SV-TO cells were analysed shortly after 
transduction and sorting, while much time passed between 
infection, selection and chromosome analysis in the SH-TO 
cell line. Given that the chromosome damage induced by 
SV40LT is an active process that gradually increases with 
serial cell passage [42] (Supplementary Figure 5D), the 
prompt analysis of the SV-TO cell line after transduction 
avoided the adverse evolution of the karyotype.
Variable intensity of telomere dysfunction upon 
96 h sustained TRF2ΔBΔM expression in the 
modified MCF-10A cell lines
To validate the efficacy of the inducible system, we 
exposed the parental MCF-10A and the three modified 
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cell lines to doxycycline for 96 h. The expression of the 
truncated TRF2ΔBΔM protein upon DOX addition was 
demonstrated by immunoblotting protein extracts from 
untreated and DOX-treated cells with full length TRF2 
antibodies (Figure 2A and Supplementary Figure 3C).
Then, the telomere dysfunction phenotype 
was evaluated through a deep cytogenetic analysis 
of metaphase spreads from 96 h DOX-treated and 
uninduced matched cells. Overall, the frequency of 
aberrant metaphases significantly increased in the TO 
cell line expressing TRF2ΔBΔM (8.57% vs. 45.45%; p= 
0.0002), but strikingly this was not the case for SH-TO 
(55.56% vs. 67.39%; p= 0.3594) nor for SV-TO (71.05% 
vs. 82.86%; p= 0.2767) (Figure 2B and Supplementary 
Table 1). This observation was probably due to the high 
frequency of abnormal karyotypes induced by p53 or 
p53/pRb inactivation. Indeed, clear evidence of the 
telomere dysfunction phenotype was observed when only 
metaphase spreads showing chromosome fusions were 
considered (Figure 2C). TRF2ΔBΔM expression for 4 days 
induced a significant increase in metaphase cells showing 
end-to-end fusions (TO p= 0.0002; SH-TO p= 0.0072 and 
SV-TO p< 0.0001) (Supplementary Table 1). On average, 
there were 0.65 fusion events per cell in TO, 1.67 in SH-
TO and 2.14 in SV-TO after expression of the dominant 
negative form of TRF2, which is statistically higher than 
the rates observed in matched uninduced cell lines (Mann-
Whitney U-test; TO p= 0.0003; SH-TO p= 0.0035 and SV-
TO p< 0.0001) (Figure 2D and Supplementary Table 1). 
Chromosome-type fusions, i.e. dicentric chromosomes 
formed during G1 were more frequently observed than 
chromatid-type fusions, which typically originate in the G2 
phase of the cell cycle (Supplementary Figure 6). Usually 
both types of fusions involved two chromosomes, though 
multiple concatenated chromosomes were occasionally 
observed in the SH-TO and SV-TO cell lines (Figure 2E). 
At that point, in order to unambiguously demonstrate that 
telomere fusions were due to chromosome ends lacking 
sufficient TRF2 protection, we performed PNA-FISH 
experiments with pancentromeric and pantelomeric 
PNA-probes. In uninduced cells, most fusion events did 
not display TTAGGG FISH signals at the junction point, 
probably indicating DSB-DSB rejoining as origin. By 
contrast, after TRF2ΔBΔM expression, the vast majority 
of fusion events displayed telomeric FISH signals at the 
fusion point (94.29% telomere positive fusions in TO, 
84.72% in SH-TO and 91.55% in SV-TO) (Figure 3A and 
3B, and Supplementary Table 2), thus demonstrating the 
presence of telomeric DNA and validating the efficacy of 
our telomere dysfunction inducible system.
Additionally, the telomere dysfunction phenotype 
was assessed by analysing the presence of anaphase bridges. 
A minimum of 215 anaphases were examined in uninduced 
and doxycycline-treated modified cell lines (Supplementary 
Table 3). The presence of cells with chromatin bridges 
during anaphase was low in TO and SV-TO cells not 
expressing the truncated TRF2 protein (3.72% and 
4.21%, respectively). By contrast, the percentage of cells 
displaying anaphase bridges in uninduced SH-TO increased 
to 18.93%, which is statistically higher than the others (p< 
0.0001) (Figure 3C and 3D, and Supplementary Table 
3). This agrees with the high frequency of chromosome 
fusion events displayed by SH-TO cells when TRF2ΔBΔM 
was not induced (Supplementary Table 1). After 96 h 
of acute telomere dysfunction, there was a significant 
increase in cells containing anaphase bridges in all the cell 
lines expressing TRF2ΔBΔM when compared with matched 
uninduced cell lines (p< 0.0001) (Figure 3C and 3D, and 
Supplementary Table 3).
Overall, the expression of TRF2ΔBΔM during 96 h 
leads to a telomere-dysfunction phenotype whose level 
of intensity depends on the functionality of cell cycle 
checkpoints. TO cells, which are p16INK4a-deficient but 
present wild-type p53, showed the lowest percentage 
of cells with end-to-end fusions, as well as the smallest 
frequency of fusions per cell. In sharp contrast, the 
telomere-dysfunction phenotype was exacerbated in the 
SV40 LT antigen transduced cells, thus confirming that 
disabled cell-cycle checkpoints allow the accumulation 
and survival of cells containing telomere damage.
Acute telomere deprotection fires BFB cycles but 
prevents the development of CIN
Cells undergoing telomere dysfunction set in motion 
BFB cycles that, following chromatin bridge resolution, 
give rise to chromosome structural aberrations, gains 
and losses of chromosomes (aneuploidy) and regional 
amplification (reviewed by [7, 43]). Most recently, 
chromothripsis and kataegis have also been documented to 
occur after chromatin bridge fragmentation [44]. Besides 
that, several studies in human cells and in the mouse have 
clearly shown that deprotection of chromosome ends leads 
to polyploidisation events [45, 46].
To evaluate the presence of telomere-dependent 
CIN we analysed for BFB cycles scars in the form of 
structural chromosome aberrations other than end-to-end 
fusions. Structural reorganisations such as non-clonal 
non-reciprocal translocations (NRT) were few and did not 
increase after TRF2ΔBΔM expression. This result was quite 
unexpected, given the significant increase of cells with 
chromatin bridges after telomere damage.
Besides that, FISH analysis with three different 
centromeric specific probes was also conducted to 
ascertain whether TRF2ΔBΔM expression engendered 
numerical chromosome changes. Chromosomes #6, 
#12 and #17 were selected for their uninvolvement in 
numerical aberrations in the parental MCF-10A and 
uninduced cell lines (Supplementary Figure 2). The 
specificity of the centromeric probes was determined 
on metaphase chromosomes (Figure 4A) and aneuploid 
configurations were evaluated in a minimum of 
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Figure 2: TRF2ΔBΔM expression induces chromosome end-to-end fusions in all inducible cell lines. (A) Immunoblots of 
MCF-10A, TO, SH-TO and SV-TO cell lines with and without DOX and HEK 293T. After 96 h of DOX treatment, the inducible cell lines 
expressed the truncated TRF2ΔBΔM protein (50 kDa); in contrast, uninduced cell lines, MCF-10A parental cell line and HEK 293T cells 
displayed only the endogen TRF2 protein (66 kDa). Lamin B1 was used as loading control. (B) After sustained expression of TRF2ΔBΔM 
for 96 h there was a significant increase in aberrant metaphases only in TO cells when compared to uninduced matched cells. (C) 
Nevertheless, the efficacy of the inducible system was validated by the statistical increase of cells with end-to-end fusions in all inducible 
cell lines. (D) Moreover, a high incidence of fusions per cell was found in all modified cell lines after sustained TRF2 depletion. Data was 
presented as mean + SEM. (E) Example of TO, SH-TO and SV-TO karyotypes after 96 h of TRF2ΔBΔM expression. Open arrows indicate 
clonal aberrations in the parental MCF-10A cell line. Insets in the karyotype show rearranged chromosomes stained with centromeric 
(green) and telomeric (red) PNA probes. Note the presence of telomere FISH signals at the fusion point of chromatid- or chromosome-
type end-to-end fusions.
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284 interphase nuclei of treated and untreated cells 
(Supplementary Table 4). The percentage of 2N aneuploid 
cells ranged from 4.66% to 14.10% and, upon doxycycline 
addition, this fraction did not increase in any of the 
modified cell lines (p= 0.0743, p= 0.9162 and p= 0.2567, 
for TO and SH-TO and SV-TO, respectively) (Figure 4B 
and 4C). Tetraploid events in uninduced TO cells were 
few (Figure 4C and 4D), but according to the role of p53 
in limiting the proliferation of polyploids, the fraction of 
tetraploid cells in untreated SH-TO and SV-TO cells was 
significantly higher than in TO (p< 0.0001 and p= 0.0094, 
respectively). Nevertheless, tetraploidisation events in 
SV-TO cells were significantly fewer than those in SH-
TO cells, which was unexpected considering that SV40LT 
also inhibits p53 function. Strikingly, upon TRF2ΔBΔM 
expression the fraction of tetraploid cells was exacerbated 
only in SH-TO cells (p= 0.0099). This result was quite 
surprising as given the elevated level of end-to-end 
fusions in SV-TO metaphases, we rather expected similar 
results for the SV-TO cell line. However, such was not the 
case, and indeed we found that the fraction of 4N cells 
in induced SV-TO was similar to that observed in treated 
TO cells (p= 0.3349). Moreover, the fraction of tetraploid 
cells displaying aneuploid configurations increased upon 
TRF2ΔBΔM expression when p53 was attenuated (2.78% 
vs. 7.04% in SH-TO and 0.86% vs. 1.91% in SV-TO), 
however statistical significance was only denoted for SH-
TO cells (p= 0.0059) (Figure 4C).
As a whole, chromosome banding of metaphase 
spreads and centromeric-specific FISH analysis in 
interphase nuclei demonstrated the failure of long-term 
telomere deprotection to induce extensive structural and 
Figure 3: TTAGGG-positive fusions and anaphase bridges after sustained TRF2ΔBΔM expression. (A) TRF2ΔBΔM expression 
significantly increased the percentage of fusion events displaying TTAGGG repeats at the fusion point, thus confirming that fusions 
occurred because of the unfolded t-loop structure and not telomere DNA shortening. The number of events of each category is shown above 
the bars. (B) TRF2 stripped telomeres mostly fused at the G1 cell cycle phase, giving rise to chromosome-type fusions. Chromatid-type 
fusions that formed in G2 were also observed, although to a lower extent. (C) The expression of TRF2ΔBΔM also increased the proportion of 
anaphase cells with chromatin bridges, another marker of telomere dysfunction. Data are presented as mean + SEM from three independent 
experiments. (D) Representative images of anaphase cells without (left) and with (right) chromatin bridges. Scale bar corresponds to 10 μm.
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numerical changes compatible with ongoing BFB cycles. 
Therefore, these data suggest that sustained 96 h of acute 
telomere deprotection prevents active proliferation of cells 
suffering telomere damage.
Transient cycles of 96 h acute telomere damage 
results in proliferation defects in the absence of 
cell cycle alterations, DDR activation and visible 
senescent and apoptotic markers
Whereas persistent disruption of TRF2 activates a 
DDR that signals cell cycle arrest or apoptosis [23, 24], 
the fate of cells experiencing transient periods of acute 
telomere deprotection remains unclear. To this end, cell 
cycle progression studies were conducted in the modified 
MCF-10A cell lines after switching on/off TRF2ΔBΔM 
expression. First, we analysed DOX-mediated cell cycle 
profile changes in unmodified MCF-10A cells to assess 
potential detrimental effects of DOX on cell proliferation 
[47]. After 24 h or 96 h exposure, we did not find evidence 
that 1 μg/ml DOX affected the cell cycle profile of 
unmodified MCF-10A cells (Mann-Whitney U-test; p> 
0.05) (Supplementary Figure 7).
Then, asynchronous untreated cultures, subjected 
to doxycycline for 96 h, as well as those recovered after 
one or two cycles of 96 h DOX exposure and washout, 
were monitored by FACS analyses of DNA content. No 
significant alterations were observed in the cell cycle 
Figure 4: Tetraploidisation is not the usual fate of cells experiencing sustained TRF2ΔBΔM expression. (A) Representative 
image of a diploid metaphase, showing the specificity of the centromeric probes tested: chromosomes 6 (red), 12 (yellow) and 17 (green). 
Scale bar corresponds to 20 μm. (B) Representative images of diploid and tetraploid cells with euploid and aneuploid configurations of 
tested centromeric probes. Scale bar corresponds to 10 μm. (C) Aneuploid configurations after TRF2 depletion only increased in the 4N 
fraction of SH-TO cells. (D) Percentage of tetraploid cells before and after TRF2ΔBΔM expression. Tetraploid cells significantly increased 
in the SH-TO cell line after DOX treatment. In contrast, this was not the case for TO or SV-TO cell lines (p= 0.0375 and p= 0.3122, 
respectively; Bonferroni p-value correction= 0.0167).
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Figure 5: Absence of cell cycle profile disturbances after long TRF2ΔBΔM expression periods. (A) Representative cell cycle 
profiles of TO, SH-TO and SV-TO cell lines during the first cycle of 96 h DOX treatment and their respective controls. Cell cycle profiles 
remained stable throughout the time of the experiment. Cell cycle phases are marked and values indicated. (B) Cell cycle phases distribution 
among TO, SH-TO cell lines (first and second cycle) and SV-TO cell line (first cycle) after 96 h DOX experiments. No statistical differences 
were observed between control and treated samples (Mann-Whitney test). A minimum of 10,000 cells were analysed per experiment. Data 
are presented as mean + SEM from three independent experiments, except for SV-TO cell line, in which only one experiment is shown.
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profile of the modified cell lines after 96 h of sustained 
TRF2ΔBΔM expression or after three days release (first 
DOX cycle) (Mann-Whitney U-test; p> 0.05) (Figure 5A 
and 5B). Moreover, exposure of TO and SH-TO cells to a 
second cycle of TRF2ΔBΔM expression did not perturb the 
cell cycle profile either (Mann-Whitney U-test; p> 0.05). 
These observations agreed with the absence of changes in 
the S-phase index after 96 h telomere damage analysed 
through incorporation of BrdU (data not shown, only 
one experiment). Although the cell cycle arrest was not 
detected, TRF2ΔBΔM sustained expression during four days 
resulted in a significant reduction of cell proliferation in 
both TO and SH-TO cells (Mann-Whitney U-test; TO p= 
0.0087; SH-TO p= 0.0032) (Figure 6A). Despite the fact 
that end-to-end telomere fusions can slow progression 
through mitosis thus misleading cell proliferation changes, 
the absence of genomic instability compatible with 
ongoing BFB cycles also supports the notion that cells 
stop proliferation and ultimately senesce or die. However, 
no obvious senescent morphology was observed in the 
modified MCF-10A cells undergoing TRF2 depletion 
(Figure 6A). Furthermore, TRF2ΔBΔM expressing cells 
were indistinguishable from control cultures by SA-β-
galactosidase activity staining (Kruskal Wallis and Dunn’s 
multiple comparison test; p> 0.05) (Figure 6B), which 
agrees with studies reporting abrogation of senescence in 
p16INK4a-deficient cells [48]. These results together with 
the observation that apoptosis is triggered in p16INK4a-
deficient mammary adenocarcinoma MCF7 cell line 
upon TRF2ΔBΔM expression [23], evoked that the reduced 
proliferation in the modified MCF-10A cells was most 
likely due to cell death resulting from telomere damage. 
Nonetheless, a marked appearance of a Sub-G1 fraction 
of cells by FACS analysis compatible with apoptosis was 
not observed after 96 h TRF2ΔBΔM expression (Figure 5A).
What is more, the response of several proteins 
involved in the DDR was considerably reduced in 
cells constitutively expressing TRF2ΔBΔM during 96 h 
when compared to cells treated with the DSB-inducer 
Bleocin™ (Figure 1C and Supplementary Figure 3A). 
Monoubiquitination of H2AX (ub-H2AX), which 
functions as a proximal regulator in the DDR by 
initiating the DNA damage signalling through efficient 
γ-H2AX formation [49] was prominent in TO, SH-TO 
and SV-TO cells exposed to Bleocin™. By contrast, in 
DOX treated TO and SH-TO cells there was a reduced 
level of ub-H2AX. Only SV-TO cells showed a marked 
higher level of ub-H2AX, which could be related to the 
focal accumulation of γ-H2AX associated with SV40LT 
antigen infection [50]. Furthermore, expression of p53, 
p53S15 and p21Waf1/Cip1 followed the same trend, with a 
higher induction in Bleocin™ treated cells. In the face of 
telomere dysfunction induced by TRF2ΔBΔM expression, 
neither p53 nor p53 phosphorylation and p21Waf1/Cip1 
upregulation could be detected in TO and SH-TO cells. 
As a whole, no evidence that 96 h of telomere dysfunction 
precipitates a DDR in the p16INK4a-deficient MCF-
10A cells was found. This low level of DNA damage 
elicited after TRF2 depletion could be the reason for the 
ambiguous fate of cells carrying telomere damage.
Even transient cycles of 24 h acute telomere 
dysfunction do not result in massive CIN
Given that acute telomere dysfunction for 96 h 
impacted on the development of CIN and the growth rate 
of cells with telomere damage, we investigated whether 
shorter periods of telomere deprotection would allow the 
generation of endless BFB cycles and massive CIN.
Both TO and SH-TO cells were exposed to 
successive 24 h periods of DOX treatment and washout. 
Cells retrieved after one or further 24 h DOX periods 
showed also an unaltered cell cycle profile (Mann-Whitney 
U-test; p> 0.05) (Figure 7A and 7B). Moreover, cells that 
received five cycles of 24 h DOX and recovery retained the 
parental MCF-10A karyotype. Chromosome aberrations in 
the form of end-to-end fusions were observed, but no signs 
of ongoing BFB cycles were present in metaphase cells 
of TO or SH-TO after five 24 h DOX cycles. In addition, 
oligoFISH analysis revealed a significant reduction in 
aberrant cells after the fifth 24 h DOX cycle compared 
to uninduced matched cells (p= 0.0244 and p= 0.0006 
for TO and SH-TO, respectively) (Figure 8A). In view 
of these results, expression of TRF2ΔBΔM was evaluated 
in those cells subjected to the fifth doxycycline cycle to 
determine whether the unperturbed cell cycle profile and 
the decreased frequency of aneuploid configurations, at 
that time, were due to an increase outgrowth of cells with 
diminished TRF2ΔBΔM expression. However, this was not 
the case, as western blot analysis demonstrated that cells 
retained TRF2ΔBΔM expression during the fifth cycle of 24 
h DOX in much the same way that cells express TRF2ΔBΔM 
after 96 h of doxycycline (Figure 8B and Supplementary 
Figure 3C). Then, we verified that 24 h of DOX exposure 
were sufficient to induce TRF2ΔBΔM expression and that, 
after DOX washout, TRF2ΔBΔM levels were reduced 
(Figure 8C and Supplementary Figure 3C). Finally, the 
efficacy of 24 h of DOX exposure in promoting uncapped 
telomeres was revealed by the presence of primary end-to-
end fusions and telomere dysfunction induced foci (TIFs) 
in mitotic cells (Figure 8D).
Together, these results somehow support the notion 
that p16INK4a-deficient MCF-10A cells, even in an impaired 
p53 background, cannot withstand short periods of acute 
telomere damage and are designated to stop proliferation 
and die.
DISCUSSION
In human primary cells replication-dependent 
telomere attrition leads to the accumulation of 
dysfunctional telomeres, which have been recognised 
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to play a relevant role in controlling the proliferative 
boundaries and fate of human cells. It is known that cells 
containing fewer than five dysfunctional telomeres can 
proliferate without halting the cell cycle [51], but above 
this threshold, cells enter senescence. Hence, the natural 
ends of chromosomes function as tumour suppressors by 
limiting the outgrowth of incipient tumour cells. At this 
point, full deprotection of telomeres is not occurring, as 
Figure 6: Reduced growth of cells displaying acute telomere dysfunction in the absence of a senescent phenotype. (A) 
Growth rate experiments in the modified cell lines after 96 h DOX exposure or after three days release from exposure demonstrate a reduced 
proliferation of cells displaying uncapped telomeres (TO cell line: 96 h DOX p= 0.0087, 96 h DOX and release p= 0.0159; SH-TO cell 
line: 96 h DOX p= 0.0032, 96 h DOX and release p= 0.2222). Analysis was performed from at least three independent experiments and 
analysed by Mann-Whitney test. Statistical analysis of SV-TO cells was not assessable (NA) due to the reduced number of replicates. At 
the right side, representative contrast field images of control and treated cells. Scale bar corresponds to 100 μm. (B) SA-β-galactosidase 
activity staining was analysed only in TO and SH-TO cell lines. The cells were exposed to 24 h or 96 h DOX and analysed after six or 
three day release, respectively. As positive control, the cells were treated with the DSBs-inducer Bleocin™ during 24 h and processed 6 
days later. Analysis was performed on three replicates and Kuskal-Wallis test and Dunn’s multiple comparison post-test. At the right side, 
representative bright field images of control and treated cells. Scale bar corresponds to 100 μm.
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Figure 7: Short TRF2ΔBΔM expression periods did not alter the cell cycle profile. (A) Representative cell cycle profiles of TO 
and SH-TO cell lines after periods of short TRF2ΔBΔM expression. The first column shows the control cells. Subsequent columns show 24 h 
of sustained DOX treatment, 24 h of DOX treatment and 7 days of release, from the first, third and fifth DOX cycle, respectively. Cell cycle 
profiles remain stable during 24 h of DOX treatment, as well after their release during five cycles of TRF2ΔBΔM expression. Cell cycle phases 
are marked and values indicated. (B) Cell cycle phases distribution among TO and SH-TO cell lines after 24 h DOX exposure experiments. 
No statistical differences were observed between control and DOX samples treated during 24 h (Mann-Whitney test). Data are presented as 
mean + SEM from three independent experiments, except for 24 h of DOX treatment and release of the first, the third and the fifth cycles, 
in which only one experiment is shown. A minimum of 10,000 cells were analysed per experiment.
Oncotarget27163www.oncotarget.com
end-to-end chromosome fusions are not observed [51]. 
Circumvention of this growth arrest, in most human cells, 
needs combined inactivation of p53 and pRb pathways. 
Strikingly, primary HMECs cultured in vitro can avoid 
the M1 growth arrest by spontaneous silencing of the 
CDKN2A gene through promoter hypermethylation [52, 
53]. In the absence of p16INK4a expression, HMECs acquire 
an extended lifespan, where further telomere shortening 
results in the progressive transit of telomeres from a 
closed state to an uncapped state. As human telomeres 
are heterogeneously sized, physiological telomere 
erosion in vHMECs leads to the gradual appearance of 
unprotected telomeres that are continuously repaired by 
fusing with each other [5]. This reduces the initial damage 
and allows massive remodelling and scrambling of the 
genome through endless BFB cycles on proliferating 
cells (reviewed in [43]). Nevertheless, these proliferating 
unstable cells finally succumb to p53-dependent growth 
arrest, called agonescence, or crisis if p53 function is 
abrogated [54]. It is thought that stabilisation of telomere 
length in these genome unstable cells would alleviate DNA 
damage and rescue cellular fitness at a cost of driving to 
malignancy.
With the aim of generating immortal mammary cells 
that have passed through a period of telomere instability, 
we have set up a reversible system of acute telomere 
deprotection by controlling the expression of TRF2ΔBΔM 
in the p16INK4a-deficient MCF-10A breast epithelial cell 
line. We hypothesised that transient periods of telomere 
dysfunction through shelterin modification in telomerase 
Figure 8: Short cycles of TRF2ΔBΔM expression do not generate unstable cells. (A) Reduction in 2N-aneuploid cells in TO and 
SH-TO cell lines when repeated TRF2ΔBΔM expression periods were induced (p= 0.0064 and p= 0.0036, respectively). (B) Immunoblot of 
TRF2ΔBΔM expression in TO and SH-TO cells denotes that the expression of TRF2ΔBΔM was not diluted over time. Protein levels during the 
fifth 24 h DOX treatment were similar to those observed after 96 h of sustained acute telomere deprotection. Lamin B1 was used as loading 
control. (C) Immunoblot of TRF2ΔBΔM expression after 24 h or 96 h of sustained DOX treatment and after 3 days of recovery from 24 h DOX 
in TO and SH-TO cell lines. Note that 24 h of DOX treatment was enough to induce the expression of TRF2ΔBΔM and protein levels were 
similar between 24 h and 96 h of sustained TRF2ΔBΔM expression. Three days after DOX removal, TRF2ΔBΔM was still present but to a lesser 
extent. Lamin B1 was used as loading control. (D) Representative images of γH2AX foci (green) and telomere (red) PNA hybridisation in 
metaphase TO and SH-TO cells. TIFs were observed in both cell lines after 24 h of sustained DOX treatment. Insets indicate colocalisation 
of γH2AX foci and telomere DNA. Scale bar corresponds to 5 μm in the images and to 2 μm in the insets.
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proficient cells would drive BFB cycles and produce some 
degree of ongoing instability at a level compatible with 
cell viability. Our study demonstrates that controlled TRF2 
depletion efficiently produced a telomere dysfunction 
phenotype in the modified MCF-10A cell lines. 
Nevertheless, we did not find clear evidence of ongoing 
BFB cycles, such as secondary chromosome aberrations 
with interstitial telomeric DNA sequences, increased 
aneuploid configurations in interphase nuclei or the 
accumulation of cells with 8C DNA content compatible 
with cycling polyploids. Despite the fact that the increased 
fraction of anaphase cells with chromatin bridges could 
reflect cell cycle progression, the lack of telomere-
dependent CIN somehow denotes the absence of long 
term proliferation of cells with telomere damage. Indeed, 
reduced cell growth was discernible in the modified 
cell lines exposed to TRF2ΔBΔM. But the proliferation 
defects were not accompanied by cell cycle disturbances 
or visible markers of senescence or apoptosis. What is 
more, 96 h of telomere dysfunction did not precipitate a 
DDR comparable to the one elicited by the DSBs-inducer 
Bleocin™. The low level of DNA damage inflicted after 
TRF2 depletion could be the reason for the ambiguous 
disappearance of cells carrying telomere damage. 
Thus, it seems likely that TRF2ΔBΔM expression induces 
proliferation defects in p16INK4a-deficient MCF-10A breast 
epithelial cells that conclude in their clearance from the 
cell culture, presumably because of a telomere capping 
defect rather than cell death associated with telomere-
dependent extensive genome instability.
In contrast to progressive telomere shortening, 
the expression of TRF2ΔBΔM suddenly evokes the 
direct transition of several telomeres from a closed to a 
deprotected state [27, 55]. In primary fibroblasts, the 
cellular response to TRF2ΔBΔM expression somehow 
recapitulates telomere-dependent replicative senescence, 
but cells stop division, displaying telomere-to-telomere 
fusions, chromatin bridges at anaphase, and nearly 
tetraploid karyotypes [20, 22, 23]. The growth arrest 
imposed by TRF2 deletion in primary fibroblasts is 
overridden by combined inactivation of p53 and pRb 
pathways through SV40LT [20] or HPV16 E6E7 [56] 
infection. Also, when p16INK4a inhibition is combined with 
p53 inactivation, a nearly complete bypass of telomere-
induced senescence is achieved [48]. Even though, the 
telomere damage inflicted results, in all instances, in 
lethal genome instability [20, 48, 56]. Unlike fibroblasts, 
the proliferation restraint elicited by sustained TRF2ΔBΔM 
expression in p16INK4a-deficient MCF-10A cells was not 
circumvented by short hairpin p53 inactivation, thus 
revealing a distinct cellular response of the mammary 
epithelial lineage to TRF2 depleted telomeres. Such 
cell lineage discrepancy was probably not related to the 
intensity of the telomere damage inflicted, as the rate of 
cells containing end-to-end fusions and the frequency of 
end fusions per cell were similar between the Jacobs and 
de Lange study and the results presented herein [48]. The 
most likely interpretation is that epithelial cells showing 
p16INK4a deficiencies are highly sensitive to acute DNA 
damage derived from sustained TRF2ΔBΔM expression and 
are committed to stop proliferating and probably die. This 
assumption is also reinforced by the presence of meta-
TIFs after 24 h TRF2ΔBΔM expression and by the karyotype 
analysis of cells retrieved after transient periods of short 
TRF2ΔBΔM expression. The reduction in the telomere insult 
to shorter periods again demonstrated a lack of hallmarks 
compatible with ongoing BFB cycles. Altogether, these 
data suggest that even brief TRF2 depletion periods 
in p16INK4a-deficient MCF-10A cells leads to a level 
of telomere damage that is incompatible with cell 
proliferation, and supports the view that the telomere 
insult itself, and not the genomic instability associated 
with BFB cycles, is responsible for the deleterious effects 
on cell proliferation [57].
In summary, the severity of the cellular responses 
to progressive or acute telomere dysfunction are not 
analogous among mammary epithelial cells and seems 
to be dependent on the severity of the telomere damage 
impinged. p16INK4a-deficient breast epithelial cells react to 
the minor damage of progressive telomere uncapping by 
stimulating repair and cell survival at a cost of unleashing 
genome instability through the onset of BFB cycles [43]. 
Conversely, TRF2-depleted telomeres in p16INK4a-deficient 
mammary MCF-10A cells results in a proliferative block 
that prevents the generation of genome unstable cells. This 
halt in cell cycle progression is not due to the sustained 
telomere damage, as even transient cycles of short TRF2 
deprotection were unable to drive chromosome instability. 
We propose that the deprotection of many telomeres 
simultaneously, above a certain DNA damage threshold, 
probably results in a local activation of the cellular stress 
response that consequently triggers cell withdrawal from 
cell cycle to maintain genomic integrity.
MATERIALS AND METHODS
Cell lines
Non-transformed human mammary epithelial 
MCF-10A cells, provided by Dr Carme Nogués, and 
derived cell lines were cultured in DMEM:F12 (GIBCO, 
ThermoFisher Scientific) supplemented with 2% 
tetracycline-free horse serum (GIBCO), cholera toxin 
(100 ng/ml) (Sigma-Aldrich), hEGF (20 ng/ml) (Sigma-
Aldrich), hydrocortisone (0.5 μg/ml) (Sigma-Aldrich), 
insulin (10 μg/ml) (Sigma-Aldrich) and 1% penicillin/
streptomycin (GIBCO). Post-stasis variant human 
mammary epithelial cells (vHMECs) were obtained from 
Cell Applications Inc. (San Diego, CA, USA). Pre-stasis 
HMECs were established from reduction mammoplasty 
tissue in accordance with previously reported methods 
[58]. The patient signed a written consent form allowing 
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their tissue to be used for biological research; this consent 
was obtained by the medical staff at the hospital prior 
to surgery. All work with human derived material was 
reviewed and approved by the Human Subjects Protection 
Committee of the Universitat Autònoma de Barcelona. 
vHMECs and HMECs were cultured with serum-free 
MEpiCM medium supplemented with MEpiCGS and 
penicillin/streptomycin (all from ScienCell Research 
Laboratories, Carlsbad, CA, USA), or with M87AX 
[59]. HEK 293T cells were cultured in DMEM (GIBCO) 
supplemented with 10% of foetal bovine serum (GIBCO) 
and 1% of penicillin/streptomycin.
Growth conditions were 5% CO2 and 37ºC. Culture 
population doublings (PDs) were calculated using the 
formula: PD = PDinitial + log2 (Nfinal/Ninitial), where Ninitial is 
the number of viable cells plated, and Nfinal is the number 
of viable cells harvested.
Lentiviral vectors
A lentiviral tetracycline-inducible TRF2ΔBΔM 
construct was generated by cloning the inducible TRF2ΔBΔM 
cassette from a pBluescript.KS vector (courtesy of Dr 
Lenhard Rudolph) into a neomycin resistant promoter-
less lentivector (Amsbio) using X-baI restriction sites. The 
Tet-regulated transcriptional transactivator protein rtTA3 
containing hygromycin resistance was a kind gift from Dr 
Iain Fraser. The lentiviral construct for p53 short hairpin 
RNA (shp53 pLKO.1 puro) was from Dr Bob Weinberg 
(Addgene plasmid #19119), and the lentiviral plasmid for 
SV40LT (pRRLsin-SV40 T antigen-IRES-mCherry) was 
from Dr Snorri Thorgeirsson (Addgene plasmid #58993). 
The hTERT lentivirus was supplied by Viral Vector 
Facility, CNIC, Spain.
Lentivirus production and transduction
To generate lentiviral particles, the psPAX2 and 
pMD2.G plasmids together with the plasmid containing 
the gene of interest were introduced in HEK 293T 
packaging cells using Calphos Mammalian Transfection 
kit (Clontech). Supernatants were collected at 48 and 72 h 
post-transfection and concentrated using Amicon 100,000 
centrifugal filter units (Merck-Millipore).
The MCF-10A T/O TRF2ΔBΔM (TO) cell line was 
generated by lentiviral transduction of MCF-10A cells 
with the TRF2ΔBΔM inducible cassette and the rtTA3 
transactivator, with polybrene (4 μg/ml) (Sigma-Aldrich). 
Transduced cells were selected first with G418 (300 μg/
ml) (Sigma-Aldrich) and afterwards with hygromycin (300 
μg/ml) (Sigma-Aldrich). The MCF-10A T/O TRF2ΔBΔM-
SHP53 (SH-TO) was generated by lentiviral transduction 
of shp53 and selection with puromycin (0.75 μg/ml). The 
MCF-10A T/O TRF2ΔBΔM-SV40LT (SV-TO) cell line was 
generated by transduction of MCF-10A T/O TRF2ΔBΔM 
with SV40LT-mCherry lentiviral particles. Selection of 
the different transduced cells was performed through one 
week culture with the appropriate antibiotic or, in the case 
of SV-TO cells, through FACS sorting of mCherry positive 
cells.
vHMECs expressing hTERT (vHMEC-hTERT) 
were generated by lentiviral transduction of vHMECs 
with the hTERT lentivirus at PD 21. HMECs-hTERT 
expressing SV40LT were generated by lentiviral 
transduction of SV40LT-mCherry lentiviral particles at 
passage 2 (PD 6.92).
Expression of TRF2ΔBΔM
Induction of telomere dysfunction in the different 
conditional cell lines was performed by culturing the 
cells with regular MCF-10A medium containing 1 μg/ml 
doxycycline (DOX) (Sigma-Aldrich). Long-term telomere 
dysfunction experiments consisted of the persistent 
exposure of cells to DOX for 96 h. In all experiments, 
fresh DOX was added to the cell culture each 48 h. 
Moreover, conditional studies were conducted where 
telomere dysfunction was switched on and switched off 
by the addition/removal of DOX from the culture medium. 
Long-term exposure cycles consisted of 96 h of sustained 
TRF2ΔBΔM expression and 3 days without DOX, whereas in 
short-term cycles, cells where treated with DOX for 24 h 
and then were exposed to DOX-free medium for 7 days.
Western blotting
Proteins were extracted with 2% SDS, 67 mM Tris 
HCl (pH 6.8) or RIPA lysis buffer, containing protease and 
phosphatase inhibitors. Protein extracts were sonicated 
twice at 25% amplitude for 15 s, boiled at 95ºC for 15 
min and centrifuged at 20,000 g for 10 min. Proteins 
were quantified using the BCA method and absorbance 
was read at 540 nm with a Victor3 spectrophotometer 
(PerkinElmer). The proteins (30 μg) were separated using 
3-8% Tris-acetate or 10% Bis-Tris gels (Life Technologies, 
ThermoFisher Scientific) at 35 mAmp and transferred onto 
nitrocellulose or PVDF membranes at 30 V. Membranes 
were blocked with 5% non-fat milk or BSA. Primary 
antibodies used were: mouse anti-SV40 st+LT Ag (Santa 
Cruz; sc-148), rabbit anti-pRbS807/811 (Cell Signaling; 
D20B12), mouse anti-pRB (Cell Signaling; 4H1), rabbit 
anti-p53S15 (ThermoFisher Scientific, 14H61L24), mouse 
anti-p53 (ThermoFisher Scientific, DO-1), mouse anti-
γH2AX (Upstate; 07-164), rabbit anti-p21Waf1/Cip1 (Cell 
Signaling; 12D1) and mouse anti-TRF2 (Novus Biologicals; 
4A794.15). Furthermore, mouse anti-α-Tubulin (Sigma, 
B-5-1-2) and rabbit anti-lamin B1 (Abcam; ab16048) 
were used as loading controls. Primary antibodies were 
incubated overnight at 4ºC. Secondary anti-mouse or anti-
rabbit horseradish peroxidase (HRP) conjugated antibodies 
were used and incubated for 1 h at room temperature. 
Chemiluminescent detection was performed using HRP 
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solution and luminol (Life Technologies), and images were 
acquired using Chemidoc, processed with Quantity One 
software and analysed with ImageLab™ 6.0.0 (BioRad).
Drug treatments
DSBs were generated in MCF-10A and 
derivatives through exposure to the radiomimetic drug 
Bleocin™ (Calbiochem, Merck-Chemicals; Germany), 
a bleomycin compound, at a final concentration of 2.5 
μg/ml. The drug was washed out after 1 h exposure and 
the cells were left to recover for 60 min before protein 
extraction.
Colcemid (GIBCO) at a final concentration of 50 
ng/ml was added to asynchronously proliferating TO, SH-
TO and SV-TO cells. After 24h of colcemid exposure, the 
cells were collected and fixed in 70% ethanol and kept 
frozen until FACS processing. Additional experiments 
consisted of 24 h colcemid treatment, washout and 24 h or 
48 h release before fixation.
Obtaining metaphase cells and end-to-end fusion 
scoring criteria
Exponentially growing MCF-10A and, untreated 
and doxycycline-treated MCF-10A modified cell lines 
were exposed to colcemid (0.5 μg/ml) for 2 h. Cells 
were trypsinised, swollen in 0.075 M KCl and fixed in 
methanol:acetic acid (3:1). Cell suspensions were dropped 
onto clean slides and stored at -20ºC until use. For end-
fusion scoring purposes, slides were first stained with 
DAPI. Then, the metaphase plates were captured and the 
karyotype was performed by reverse DAPI staining, which 
results in a reproducible G band-like pattern that allows for 
accurate individual chromosome identification before the 
chromosomes became swollen by the denaturation step. 
Afterwards, the slides were hybridised with the PNA probes 
and the metaphases were relocated to analyse the telomere 
and centromere status of each chromosome. A fusion event 
was considered when the connection between chromatids (1 
or 2) was verified on the initial DAPI stained image. This 
procedure reduces the possibility of end-fusions events 
being confused with mere alignment of chromosomes.
In situ fluorescence hybridisation
Telomere and centromere PNA-FISH
Metaphase spreads were hybridised with pantelomeric 
(Rho-(CCCTAA)3, PE Biosystems) and pancentromeric 
(FITC-AAACACTCTTTTTGTAGA, Panagene) PNA 
probes. Denaturation took place at 80ºC for 3 min and 
hybridisation was performed at 37ºC for 2 h in a humid 
chamber. Afterwards, slides were washed twice with 70% 
formamide for 15 min, followed by three TNT (Trizma Base 
50 mM, NaCl 150 mM and Tween20 0.25%) washes for 5 
min. Dehydrated slides were counterstained with DAPI.
OligoFISH
Interphase nuclei spreads were treated with pepsin-
HCl at 37ºC for 10 min, post-fixed with formaldehyde-
MgCl2 and denatured with 70% formamide at 74ºC. Specific 
centromeric probes for chromosomes 6 (Gold DY539), 12 
(Red DY590) and 17 (Green DY490) (Cellay, Inc.) were 
hybridised for 2 h in a humid chamber followed by one 5 
min wash with 0.2xSSC-0.1%SDS at 50ºC and a 2xSSC 
wash. Cells were dehydrated and counterstained with DAPI.
DAPI staining, immunofluorescence and TIFs 
(telomere dysfunction induced foci)
For anaphase bridge scoring, cells cultured on 
coverslips were fixed with 4% paraformaldehyde 
(PFA) at 37ºC, rinsed twice in PBS, allowed to dry and 
counterstained with DAPI.
For immunofluorescence, cells were fixed in 4% 
PFA for 10 min at 37ºC, permeabilised with 1% Triton 
X-100 at room temperature and blocked with 5% FBS-
0.1% Triton X-100- KCM buffer. Then SV40 st+LT Ag 
(1:200) primary mouse antibody was incubated overnight 
at 4ºC. Conjugated chicken Alexa Fluor 488-antimouse 
antibody (1:500, ThermoFisher Scientific) was incubated 
for 1 h. Cells were counterstained with DAPI.
For the TIF assay, cells were treated with DOX 
for 24 h. The following day, chromosome spreads were 
obtained as described by [60]. Briefly, after 25 min of 
colcemid (20 ng/ml), the cells were trypsinised and 
resuspended to a final concentration of 5x104 cells/ml 
in hypotonic solution (0.2% Trisodium Citrate-0.2% 
KCl). Thereafter, the cells were cytocentrifuged 10 min 
at 1,000 rpm and the slides were air dried. Afterwards, 
the slides were treated with pre-extraction buffer for 
5 min, 1% Triton X-100- KCM buffer for 10 min and 
fixed with 4% PFA for 10 min. Permeabilisation was 
also performed with chilled absolute methanol during 
20 min. Cells were blocked with 2% FBS-0.1% Triton 
X-100- 100 μg/ml RNAse- TrisNaCl for 30 min at 
37ºC, and mouse anti-γH2AX (1:500, clone JBW301 
Millipore) antibody was incubated at 4ºC. Conjugated 
chicken Alexa Fluor 488-antimouse was incubated for 
1 h. Slides were fixed again in 2% PFA for 10 min and 
dehydrated through an ethanol series. Samples and 
pantelomeric probe (Rho-(CCCTAA)3, PE Biosystems) 
were co-denatured at 80ºC for 4 min, and hybridised 
overnight at 37ºC in a humid chamber. Slides were 
washed once with 70% formamide-Tris and twice with 
PBST. To ensure γH2AX staining, conjugated Alexa 
Fluor 488-antimouse was re-incubated for 30 min. Cells 
were dehydrated and counterstained with DAPI.
Fluorescent microscopy and fluorescent images
Most fluorescent staining was visualised under an 
Olympus BX60 microscope equipped with epifluorescent 
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optics and a camera (Applied Imaging, Inc.). In the case 
of TIFs analysis, an Olympus BX61 epifluorescence 
microscope with motorized x-y stage (BX-UCB, Olympus) 
was used to acquire images as a Z-stack (total of 7 planes of 
2.11 μm each). The fluorochromes were visualised through 
simple filters and images were captured and analysed using 
Cytovision software (Applied Imaging, Inc.).
Flow cytometry and live cell sorting
For tracking S phase cells, a pulse of 10 μM BrdU 
was carried out for 30 minutes. Afterwards, the cells 
were rinsed, trypsinised, centrifuged and fixed with 70% 
ethanol. For cell cycle analysis or SV40 st+LT detection, 
the cells were harvested and fixed in 70% ethanol and kept 
at -20ºC until processing.
For SV40 st+LT and BrdU analysis, the fixed cells 
were permeabilised with 1xPBS-1%Triton X-100 solution. 
In the case of BrdU detection, DNA was denatured with 
HCl 2N-0.1% Triton X-100. After 30 min, denaturation 
was blocked by adding tetraborate solution (0.1 M). 
Before antibody detection, every sample was divided 
into two tubes, one for mouse anti-SV40 st+LT Ag (Santa 
Cruz; sc-148) or mouse anti-BrdU (Santa Cruz, sc32323) 
and subsequent Alexa Fluor 488-antimouse secondary 
antibody. The second tube was used as a negative control 
of the secondary antibody.
All cells were stained with propidium iodide 
solution (PBS-1% Triton X-100, propidium iodide 45 μg/
ml, and RNase 0.2 mg/ml) before cytometric processing. 
Analysis was performed under a FACSCalibur (Beckton 
Dickinson). Sample excitation was done with a 488 nm 
laser and a minimum of 10,000 events were collected 
per sample. Single cells were gated first by forward 
scatter (FSC) and side scatter (SSC), and DNA content 
of single cells was measured on FL3 (670 nm long pass 
filter) and plotted vs. number of cells. Alternatively, A488 
fluorescence was detected on FL1 (530/30 nm band pass 
filter) and was plotted vs. propidium iodide. The data were 
analysed with BD FACSDiva software v7.0.
For live cell experiments, cells were trypsinised and 
resuspended in PBS. Sorting of mCherry positive cells 
was carried out using a FACSAria I SORP sorter (Beckton 
Dickinson). Excitation of the sample was done using a 488 
nm laser for FSC and green fluorescence parameters, and 
a 561 nm laser was used for the excitation of mCherry 
and SSC signals. Cells were gated according to their FSC 
vs. SSC parameters. Red emission from mCherry (610/20 
nm) excited with the yellow laser (561 nm) was plotted 
vs. green emission (530/30 nm) from the 488 nm laser on 
a dot plot in order to discriminate mCherry positive cells.
Senescence associated beta-galactosidase staining
TO and SH-TO cells treated with DOX (1 μg/ml) 
for 24 h and 96 h and left to recover until the seventh 
day were seeded at a concentration of 7,500 cells/well. A 
positive control consisted of cells treated with Bleocin™ 
(2.5 μg/ml) for 24 h and left to recover until the seventh 
day. In Bleocin™ experiments 50,000 cells/well were 
seeded. The Senescence β-Galactosidase Cell Staining Kit 
(Cell Signaling) was used according to the manufacturer’s 
instructions. The cells were examined under a light 
microscope (Olympus IX71) and those cells with blue 
staining were considered positive for β-galactosidase 
activity. We estimated the percentage of β-galactosidase 
staining by analysing 5 individual fields per well from 
three replicates.
Statistical analysis
Data analysis was carried out with GraphPad Prism 
version 5 software (GraphPad Software Inc.). Normality 
distribution was tested by Saphiro-Wilk normality test. 
Data sets were compared using Fisher’s exact test, Mann-
Whitney test, Kruskal-Wallis test and Dunn’s multiple 
comparison post-test. P-values less than 0.05 were 
considered significant. When multiple comparisons were 
done, the Bonferroni p-value correction was applied and 
indicated.
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